Andy Kinley

Oncology clinical researcher, former scientist, immuno-oncology, cell therapy, and mountain biking in Blue Ridge Mtns

[Andy Kinley @AndyKinley]

@PeterKolchinsky You lose me when you don’t mention family members on his board getting rich off his ‘vant schemes. Hedge funder biotech. No value provided to Alz field or patients

[TMZ @TMZ]

Dr. Oz on stage with Dean Cain talks about how great the crowd is at the Great American State Fair... so @hicharliecotton pans his camera to reveal quite the opposite.

[Andy Kinley @AndyKinley]

@mbeisen Your starting assumption is not universally valid - being smart does not have to equal riches and power.

[Andy Kinley @AndyKinley]

@UVA_MIC Congratulations Alison!

[Andy Kinley @AndyKinley]

@the_transit_guy Visited Utrecht last year and loved riding around the incredible bike specific infrastructure!

[Andy Kinley @AndyKinley]

@princetongb @MaverickNY I don't think this applies to the whole patient population. Isn't SOC of PD-L1 50% or greater monotx pembro?

[Andy Kinley @AndyKinley]

@harpreet_md Welcome to the team!

[Andy Kinley @AndyKinley]

@raffcolo @AACR Payload binding selectivity enhancers (PBSE) was an interesting angle to decrease tox

[Andy Kinley @AndyKinley]

@LifeSciVC Strong disagree from me. I don't want a foreign country to be able to control the messaging to our populous and youth. Too much damage happening already from US social media companies to allow a foreign company to have the same or greater access.

[Andy Kinley @AndyKinley]

@BowTiedBiotech Validated target, antigen loss isn’t an issue, but I don’t know if it is validated in the context of a CAR-T treating autoimmune disease like CD19 CAR-T.

[Andy Kinley @AndyKinley]

@Dr_R_Kurzrock C.

[Andy Kinley @AndyKinley]

Focused on malignant hematology for the last few days at ASH and catching up on news. Interesting data for a subset of NSCLC patients...Dupixent for cancer? Researchers test blockbuster med as an immunotherapy-booster https://t.co/uhgXyV5L7W

[Andy Kinley @AndyKinley]

Interesting, hitting the buzzwords…DCT and diversity.

[Amber Tong @AmberTongPW]

AstraZeneca launches clinical services business Evinova in health tech foray 

lots of details and good quotes in this @annajbwn story, reporting from London

https://t.co/lVZ2rZ5UWi

[Andy Kinley @AndyKinley]

@eperlste @TheDawnBell I wouldn't expect the LTFU (total 15 years) data to be required for approval - see CAR-T approvals with requirement for same LTFU period.

[Andy Kinley @AndyKinley]

@onco_park I believe the rationale for CD16 engagement is to bind to NK cells creating an NK-cell engaging bispecific (analogous to CD3 binding in T cell engaging bispecifics)

[Andy Kinley @AndyKinley]

Best #ESMO23 biotech headline of the morning? "Now I know my ADCs"
@endpts

[Andy Kinley @AndyKinley]

@mkstew21 @ryanvaughan I see that too...

[Fyodor Urnov @UrnovFyodor]

TFW you type "CRISPR-Cat" instead of "CRISPR-Cas," decide this is an original pun describing gene-edited felines, and a simple google search tells you that Indoor Biotechnologies is already there.
[gr9 name - 9>8 - for a biotech given its goals]
https://t.co/Vuqxs3SvI9

[Andy Kinley @AndyKinley]

@psuvafan007 @highbrow_nobrow Careful, I'm envisioning one of your elbows getting dislocated in one of Steve's patented 80s karate moves if you bring any more of that noise.